Lincoln Pharmaceuticals share price
You have to be logged in to add this to Watchlist.- ₹552.00(-0.92%)July 11, 2025 15:28:59 PM IST
- NSE
- BSE
- Vol : 45.14K (NSE + BSE)Last 20 day avg : 42.35 K
Lincoln Pharmaceuticals is trading -0.92% lower at Rs 552.00 as compared to its last closing price. Lincoln Pharmaceuticals has been trading in the price range of 558.90 & 546.05. Lincoln Pharmaceuticals has given -29.30% in this year & -0.38% in the last 5 days. Lincoln Pharmaceuticals has TTM P/E ratio 13.41 as compared to the sector P/E of 22.90.There are 1 analysts who have initiated coverage on Lincoln Pharmaceuticals. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 11.58 Crores in its last quarter.Listed peers of Lincoln Pharmaceuticals include Bajaj Healthcare (-1.55%), Kwality Pharmaceuticals (1.23%), Lincoln Pharmaceuticals (-0.92%).The Mutual Fund holding in Lincoln Pharmaceuticals was at -% in . The MF holding has - from the last quarter. The FII holding in Lincoln Pharmaceuticals was at 5.00% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 12, 2025, 11:07 AM UTC
- Dividend YieldLower than industry0.32Annual dividends as a percentage of the stock price.
- P/BIn line with historical values1.68The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values13.67Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.55Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 18.03% from Rs 168.18 crore to Rs 142.49 crore, year-on-year
The company's profit declined by 37.76% year-on-year during the March quarter, dropping from Rs 18.60 crore to Rs 11.58 crore- Company can comfortably pay off its interest obligations with its earnings
- R1
- 584.02
- R2
- 602.33
- R3
- 621.32
- S1
- 546.72
- S2
- 527.73
- S3
- 509.42
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Bajaj Healthcare | Bearish | 478.15 | -1.55 | 1,506.89 | 34.04 | 3.29 | 0.21 | 13.93 |
| Kwality Pharmaceuticals | Bullish | 1,181.95 | 1.23 | 1,226.42 | 30.54 | 4.6 | - | 5.73 |
| Lincoln Pharmaceuticals | Bearish | 552.00 | -0.92 | 1,109.58 | 13.60 | 1.67 | 0.32 | - |
| Anuh Pharma | Neutral | 204.50 | -1.99 | 1,024.79 | 22.67 | 3.29 | 0.70 | 0.02 |
| Aayush Wellness | Bullish | 242.30 | 2.00 | 1,179.31 | 311.96 | 126.51 | - | 0.55 |
- Promoter(s) holding is moderate at 49.78%
- FIIs are invested in this company
- FIIs holding has decreased by 0.16 percentage points from previous quarter
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-22 | Audited Results & Final Dividend |
| 2025-02-13 | Quarterly Results |
| 2024-11-14 | Quarterly Results |
| 2024-08-08 | Quarterly Results |
| 2024-05-16 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE405C01035
- BSE Code531633
- NSE CodeLINCOLN
Lincoln Pharmaceuticals is trading at 552.00 as on Fri Jul 11 2025 09:58:59. This is -0.92% lower as compared to its previous closing price of 557.15.
The market capitalization of Lincoln Pharmaceuticals is 1109.58 Cr as on Fri Jul 11 2025 09:58:59.
The 52 wk high for Lincoln Pharmaceuticals is 975.00 whereas the 52 wk low is 500.00
Lincoln Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 13.41
- Sector P/E: 22.90
- Dividend Yield: 0.32%
- D/E ratio: 0.00
Lincoln Pharmaceuticals reported a net profit of 82.35 Cr in 2025.